Influence of new late effects on quality of life over time in Hodgkin lymphoma Survivors: a longitudinal survey study

• Published in: Annals of oncology Vol. 24; no. 1; pp. 226 - 230
• Main Authors: Khimani, N., Chen, Y.-H., Mauch, P.M., Recklitis, C., Diller, L., Silver, B., Ng, A.K.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.01.2013; Oxford University Press
• Subjects: Antineoplastic agents; Biological and medical sciences; Data Collection; fatigue; Hematologic and hematopoietic diseases; Hodgkin Disease - physiopathology; Hodgkin lymphoma; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Longitudinal Studies; Medical sciences; Pharmacology. Drug treatments; Quality of Life; Survival; survivorship; survivorship; fatigue; quality of life; Hodgkin lymphoma; Human; Late; Survivor; Fatigue; Hodgkin disease; Malignant hemopathy; Lymphoma; Quality of life; Survey; Follow up study; Lymphoproliferative syndrome; Cancer
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mds243

Long-term Hodgkin lymphoma (HL) survivors are known to have diminished quality of life (QoL). However, limited data are available on temporal changes in QoL and factors associated with the changes. In 2010, we conducted a follow-up questionnaire study on 273 HL survivors who participated in a 2003 questionnaire study on late effects after HL. The questionnaire items were limited to new late complications and reassessment of QoL and fatigue level, using the Short Form 36 (SF-36) and the Functional Assessment of Chronic Illness Therapy-Fatigue instruments, respectively. We compared the results from the 2003 and the 2010 questionnaires, and QoL score changes between survivors with and without new late complications during the 7-year period. There was a significant decline in the SF-36 Physical Component Summary score (median change, -1.8; P<0.0001) over the time period. The decline was significantly greater among survivors with a new cardiac (P=0.005) or pulmonary (P<0.0001) complication, compared with those without any new complications. The survivors reporting new cardiac complications also experienced significantly greater worsening of fatigue scores (P=0.004). The significant association between the development of new cardiopulmonary complications and decline in QoL and energy level of HL survivors provides further support for current efforts to reduce treatment to limit late effects.